World’s 1st Healthcare Metaverse from DeHealth

A British non-profit organization, DeHealth, is revolutionizing the healthcare industry. The company announced the start of the creation of a Decentralized Metaverse, which will take millions of doctors and patients to a new world where they can work, interact with each other in full 3D format and earn virtual assets by selling their anonymized medical data.

The HLT (health) token will become the main mean of settlement within the ecosystem that will power it from the inside.

The DeHealth Metaverse will be an extension of the VR, AR, and Mixed Reality (MR) technologies. It will allow several participants, for instance, a doctor and a patient, to communicate via one virtual space, assimilating the real-world situation.

The user’s ability to transfer their digital identity (avatar), including all medical data collected through other digital platforms, into the new virtual world without problems will be critical to the success of the DeHealth metaverse.

Anna Bondarenko, the Co-Founder DeHealth commented: “Our goal is to provide people with the most advanced technologies to preserve their health so that every person in the world, regardless of the place of residence, social status, and financial capabilities, can control their health and life. The future of healthcare lies not in treatment but the prevention of diseases. Our AI will notice the slightest deviations from the human norm and warn about it. Thanks to HLT, each person in the metaverse can sell their impersonal medical information with their own hands.”

Denys Tsvaig, the Co-Founder of DeHealth, commented: “To implement our metaverse, we will use a new technological stack: the Hospital OS digital platform, the blockchain network (cryptoeconomics of the HLT Network), fundamentally different AR / VR devices, electronic clothing, 5G communication networks, quantum computing & communications, cybersecurity, data storage chips using synthetic biology and so much more. The metaverse may require a new programming model that resembles a living and open developing platform, where millions of users seamlessly move from one world to another using the avatar of themselves.”

The DeHealth metaverse will be supported by a wide range of devices – from smartphones and PCs to mixed types of headsets.

Holders of HTL tokens will become the first investors and leaders of the new trend in healthcare.

A preliminary version of the metaverse will be available in late 2022. It will open up access to 3 million Hospital OS users, DeHealth said.

SourceDeHealth

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”